September 3, 2020 – Biosense Webster launched its Carto 3 System Version 7 and the Carto Prime Mapping Module to enhance...
This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion.
Biosense Webster's Carto Prime Mapping Module offers new tools to help shorten ablation time. Left is an example of Coherent imaging showing conduction identification, conduction velocity vectors and conduction barrier zones. Top right, Carto Finder Module automatic visualization of region of interest. Below right, LAT Hybrid imaging, showing correct identification of PVC location based on catheter location in sinus rhythm, and automated visualization of PVC points.
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.
The Linq II implantable cardiac monitor (ICM) system delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for up to 4.5 years.
Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use a small, adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer.
An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.